Ideal Acquisition Candidates Are Advanced-Stage With Good Data - IN3 Panel
This article was originally published in The Gray Sheet
Executive Summary
The most desirable acquisition candidates for established medical technology firms in the current economic climate are those in advanced stages of development with good comparative effectiveness data, according to panelists at the recent Investment In Innovation (IN3) Medical Device Summit
You may also be interested in...
Recession, Reform Efforts Put Pressure On MedTech Venture Funding Model
The recession, impending health care reform and the changing regulatory and reimbursement environment are putting pressure on the traditional medtech venture capital funding model, according to a 1report from consulting firm Ernst & Young
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.